Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epadel OTC Switch Approved With Condition Of Appropriate Use Survey

This article was originally published in PharmAsia News

Executive Summary

Japan’s Pharmaceuticals Affairs and Food Sanitation Council’s Committee on Non-prescription Drugs decided that the switch of Mochida Pharmaceuticals hyperlipidemia drug Epadel to an over-the-counter drug will be approved on the condition that a survey on appropriate use is carried out.

You may also be interested in...



Piramal Profits As It Sheds DRG To Clarivate For $950m

An experienced hand at M&A, Ajay Piramal has done it again – this time selling Decision Resources Group to Clarivate Analytics for $950m. Apart from $900m in cash, Piramal Enterprises will get a stake in Clarivate while the latter expects the acquisition to be earnings-accretive in 2020.

QUOTED. 20 January 2020. Henrik Berggren.

San Francisco-based digital health start-up Steady Health has launched the first "virtual" full-service diabetes clinic for patients in California. See what Henrik Berggren, CEO and founder of Steady Health, said about it here.

China Commits To Patent Linkage And Extensions In US Trade Deal

The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions. 

 

Topics

UsernamePublicRestriction

Register

SC079626

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel